Can Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space?

Novo Nordisk's Ozempic and Wegovy generated DKK 50.1 billion in Q1 2025, representing 66% of total revenue, driven by strong demand in the diabetes and obesity markets where NVO holds leading market share positions. Manufacturing ramp-up has resolved prior supply shortages, potentially boosting sales, though competition is intensifying from Eli Lilly, Amgen, and Viking Therapeutics as the obesity market is projected to reach $100 billion by 2030. Despite positive earnings estimate revisions, NVO shares have underperformed year-to-date, trading at a premium P/E ratio compared to the industry but below its historical average.

Analysis

Novo Nordisk's (NVO) flagship GLP-1 drugs, Ozempic and Wegovy, were pivotal in Q1 2025, contributing DKK 50.1 billion, or 66% of the company's total revenues, and underscoring NVO's leading global market shares of approximately 54% in diabetes GLP-1 and 68.7% in branded obesity treatments. The resolution of previous FDA-reported supply shortages for these drugs, due to enhanced manufacturing capacity, suggests a potential for sales rebound in subsequent quarters. Growth prospects are further supported by expanded indications for Ozempic (cardiovascular risk reduction, kidney failure in T2D patients) and Wegovy (reduction of major adverse cardiovascular events, with potential expansion for heart failure prevention), strategic marketing agreements in the U.S., and an FDA review for an oral semaglutide obesity treatment. However, the competitive landscape in the obesity market, projected by Goldman Sachs to reach $100 billion by 2030, is intensifying significantly with strong contention from Eli Lilly's (LLY) Mounjaro and Zepbound, and advancing pipelines from Amgen (AMGN) with MariTide (Phase III) and Viking Therapeutics (VKTX) with VK2735 (Phase III initiation expected this year). Despite NVO's stock underperforming year-to-date with a 13.6% loss against the industry's 2.5% gain, and trading below its 200-day moving average, earnings estimates for 2025 have risen to $3.84 per share and for 2026 to $4.64 per share. The company's forward P/E ratio of 17.67 is above the industry average of 15.63 but notably below its five-year mean of 29.26, while its trailing twelve-month return on equity stands at a strong 80.95%.

Key Decisions for Investors

• Investors should assess Novo Nordisk's dominant market position and multiple growth drivers, including new indications and resolved supply constraints, against the escalating competitive threats in the high-growth obesity sector.
• The current stock valuation, a premium to the industry but below NVO's historical levels, alongside recent share price underperformance, may present a nuanced opportunity, contingent on the company's ability to maintain its growth trajectory amidst competition.
• Continuous monitoring of competitor advancements, particularly from Eli Lilly, Amgen, and Viking Therapeutics, and their impact on NVO's market share and pricing power in the GLP-1 space is crucial for investment decisions.